-
Mashup Score: 4Real-world data: ARNI more effective in reducing adverse outcomes in HFrEF than RAAS blockade - PACE-CME - 11 month(s) ago
In a real-world, Korean HFrEF population, ARNI reduced the 1-year risk of all-cause mortality or any hospitalization compared with traditional RAAS blockade. The benefit of ARNI was more pronounced in patients with good medication adherence.
Source: PACE-CMECategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 10Pooled analyses show cardiovascular and renal benefits with ARNI in HFpEF and HFmrEF - PACE-CME - 11 month(s) ago
**ESC Heart Failure 2023** Pre-specified, participant-level pooled analyses of PARAGLIDE-HF and PARAGON-HF show that sacubitril/valsartan, compared to valsartan, reduced cardiovascular and renal outcomes in patients with HFpEF or HFmrEF.
Source: PACE-CMECategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 12Coffee consumption not associated with atrial arrhythmias in healthy individuals - PACE-CME - 1 year(s) ago
In the randomized, case-crossover CRAVE trial, the consumption of caffeinated coffee was not associated with atrial arrhythmias in healthy individuals compared to the avoidance of caffeine.
Source: PACE-CMECategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 1Effects of PCSK9i on coronary plaque morphology after 26 weeks in CAD patients - PACE-CME - 1 year(s) ago
Treatment of evolocumab for 26 weeks showed an increase in the minimum fibrous cap thickness by OCT, reduction in maxLCBI 4 mm by NIRS and reduction in atheroma volume by IVUS in non-obstructive lesions of patients with stable CAD in the YELLOW III study.
Source: PACE-CMECategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 0LDL-c not associated with future ASCVD in absence of coronary atherosclerosis at middle age - PACE-CME - 1 year(s) ago
In a large Danish cohort of middle-aged individuals with symptoms of CAD , LDL-c levels were related to the occurrence of MI and ASCVD events over ~4 years in patients with evidence of coronary atherosclerosis at baseline but not in those without.
Source: PACE-CMECategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 5
Mechanistic studies on plaque characteristics in patients receiving EPA can be insightful to understand the CV risk reductions seen in clinical trials. Prof. Budoff gives an overview of effects of EPA on multiple plaque components.
Source: PACE-CMECategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0CRISPR/Cas9-based gene editing in patients with transthyretin amyloidosis with cardiomyopathy - PACE-CME - 2 year(s) ago
**AHA 2022** A phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of NTLA-2001, a CRISPR/Cas9-based in vivo gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy.
Source: PACE-CMECategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Real world evidence with PCSK9i mAb; implications and lessons for current clinical use - PACE-CME - 2 year(s) ago
Raul Santos and Maciej Banach talk about the safety of PCSK9 mAbs and of very low cholesterol levels, and discuss the importance of patient education to improve adherence.
Source: PACE-CMECategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves - PACE-CME - 2 year(s) ago
An analysis showed that transcatheter aortic valves were less likely to have hemodynamic valve deterioration over a 5-year period compared to surgical valves. “This is potentially practice changing” said Coylewright.
Source: PACE-CMECategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1LDL-c lowering with triple therapy of statin, ezetimibe and bempedoic acid - PACE-CME - 2 year(s) ago
This phase 2 randomized clinical trial showed that initiation of triple therapy with statin, ezetimibe and bempedoic acid significantly reduced LDL-c by 60.5%, compared with placebo.
Source: PACE-CMECategories: Cardiologists, Latest HeadlinesTweet
RT @vic_pallares: Real-world data: ARNI more effective in reducing adverse outcomes in HFrEF than RAAS blockade https://t.co/2RqIRhox2Z @g…